FDA clears SurgiQuest's "breakthrough" laparoscopy kit
This article was originally published in Clinica
The US FDA has granted 510(k) clearance for SurgiQuest's 5mm AnchorPort trocars for use during single incision laparoscopic surgery. Trocars are round pens with a pointed end that are used to introduce ports for minimally-invasive surgery. The Orange, Connecticut company claims it is the world's first and only trocar with an elastic, stretchable cannula system – this adjusts to the patient's abdominal wall thickness, its distal tip anchoring the device in place within the abdominal wall and giving surgeons more freedom of movement. Conventional fixed-length trocars are rigid and protrude into the abdominal cavity, which can interfere with other surgical instruments, limiting manoeuvrability, SurgiQuest says. The AnchorPort device also has a softer outer skin so causes less trauma to tissue, the firm added.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.